Executive Vice President Lane Michael converted options into 885 shares and covered exercise/tax liability with 272 shares, increasing direct ownership by 9% to 7,103 units (SEC Form 4)
$IDXX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 02/13/2025 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 02/14/2025 | M | 160 | A | $0 | 6,650.2345(1) | D | |||
| Common Stock | 02/14/2025 | M | 204 | A | $0 | 6,854.2345 | D | |||
| Common Stock | 02/14/2025 | M | 220 | A | $0 | 7,074.2345 | D | |||
| Common Stock | 02/14/2025 | M | 301 | A | $0 | 7,375.2345 | D | |||
| Common Stock | 02/14/2025 | F | 272 | D | $444.53 | 7,103.2345 | D | |||
| Common Stock | 592(2) | I | by spouse | |||||||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Non-Qualified Stock Option (right-to-buy) | $459.76 | 02/13/2025 | A | 6,320 | (3) | 02/12/2035 | Common Stock | 6,320 | $0 | 6,320 | D | ||||
| Incentive Stock Option (right-to-buy) | $459.76 | 02/13/2025 | A | 217 | (4) | 02/12/2035 | Common Stock | 217 | $0 | 217 | D | ||||
| Restricted Stock Unit | (5) | 02/13/2025 | A | 1,468 | (5) | (5) | Common Stock | 1,468 | $0 | 1,468 | D | ||||
| Restricted Stock Unit | (6) | 02/14/2025 | M | 160 | (6) | (6) | Common Stock | 160 | $0 | 0 | D | ||||
| Restricted Stock Unit | (7) | 02/14/2025 | M | 204 | (7) | (7) | Common Stock | 204 | $0 | 204 | D | ||||
| Restricted Stock Unit | (8) | 02/14/2025 | M | 220 | (8) | (8) | Common Stock | 220 | $0 | 440 | D | ||||
| Restricted Stock Unit | (9) | 02/14/2025 | M | 301 | (9) | (9) | Common Stock | 301 | $0 | 903 | D | ||||
| Explanation of Responses: |
| 1. Includes a total of 47 shares purchased under the Issuer Employee Stock Purchase Plan on March 29, 2024, June 28, 2024, September 30, 2024 and December 31, 2024. |
| 2. Held by the reporting person's spouse in an IRA account. The reporting person disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniary interest therein. |
| 3. Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026. |
| 4. Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2029. |
| 5. Grant of restricted stock units ('RSU') that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2026. |
| 6. Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2022. |
| 7. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2023. |
| 8. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. |
| 9. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. |
| Remarks: |
| /s/ Lily J. Lu, Attorney-in-Fact for Michael Lane | 02/18/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||